ESMO TAT 2022 | Pre-clinical data for novel EGFR inhibitor BDTX-1535

Matthew Lucas, PhD, Black Diamond Therapeutics, Cambridge, MA, explains pre-clinical data for the novel EGFR inhibitor BDTX-1535. This data was collected from mouse models of glioblastoma multiforme (GBM) and non-small cell lung cancer (NSCLC). Dr Lucas discusses two key pre-clinical trials, and explains the rationale behind moving into Phase I trials of BDTX-1535 in patients who have intrinsic or acquired resistance to currently-approved EGFR inhibitors. This interview was conducted at the virtual European Society for Medical Oncology Targeted Anti-Cancer Therapies (ESMO TAT) Congress 2022.